Cubist Systematic Strategies LLC Decreases Holdings in Amylyx Pharmaceuticals, Inc. $AMLX

Key Points

• Cubist Systematic Strategies LLC reduced its holdings in Amylyx Pharmaceuticals by 82.4% in Q1, owning 83,130 shares valued at $294,000 as of its latest SEC filing.
• Other institutional investors, such as China Universal Asset Management and Hsbc Holdings PLC, have increased their stakes in Amylyx Pharmaceuticals during the same period.
• Amylyx Pharmaceuticals reported a quarterly earnings miss with a loss of ($0.46) per share, falling short of analysts' expectations, and the company's stock has an average rating of "Buy" with a consensus price target of $12.25.

Cubist Systematic Strategies LLC lessened its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 82.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 83,130 shares of the company's stock after selling 389,267 shares during the quarter. Cubist Systematic Strategies LLC owned 0.09% of Amylyx Pharmaceuticals worth $294,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Invesco Ltd. bought a new position in Amylyx Pharmaceuticals in the 1st quarter valued at $162,000. Dimensional Fund Advisors LP purchased a new position in shares of Amylyx Pharmaceuticals during the 4th quarter valued at $205,000. American Century Companies Inc. lifted its position in shares of Amylyx Pharmaceuticals by 80.4% during the 1st quarter. American Century Companies Inc. now owns 107,014 shares of the company's stock valued at $379,000 after buying an additional 47,704 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Amylyx Pharmaceuticals by 165.9% during the 4th quarter. Bank of America Corp DE now owns 2,426,263 shares of the company's stock valued at $9,171,000 after buying an additional 1,513,748 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new position in shares of Amylyx Pharmaceuticals during the 4th quarter valued at $793,000. Institutional investors own 95.84% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on AMLX. Bank of America upped their price target on Amylyx Pharmaceuticals from $10.00 to $14.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. The Goldman Sachs Group raised Amylyx Pharmaceuticals to a "buy" rating and set a $10.00 price target on the stock in a research report on Thursday, July 10th. Citigroup began coverage on Amylyx Pharmaceuticals in a report on Tuesday, June 17th. They set a "buy" rating and a $12.00 price objective on the stock. UBS Group raised Amylyx Pharmaceuticals to a "hold" rating in a report on Tuesday, June 24th. Finally, Wall Street Zen raised Amylyx Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Amylyx Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $13.25.

Amylyx Pharmaceuticals Price Performance

NASDAQ AMLX traded up $0.20 during trading on Monday, reaching $11.85. The company's stock had a trading volume of 1,926,189 shares, compared to its average volume of 1,192,567. The stock has a market capitalization of $1.06 billion, a PE ratio of -4.74 and a beta of -0.45. The firm has a fifty day moving average of $8.64 and a 200 day moving average of $6.01. Amylyx Pharmaceuticals, Inc. has a one year low of $2.59 and a one year high of $12.25.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.02). Research analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.